Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| LTGO | CLUSTER | bullish | 5/10 | Two 10% owners (Director James Tananbaum and Foresite Capital) each purchased $2.52M of LTGO stock at $18.00/share on Au | Aug 12, 2026 |
| APRE | PRESS-RELEASE | neutral | 5/10 | Aprea Therapeutics reported Q2 2026 results with a net loss of $3.6M ($-0.07/share), widening from a $3.2M loss in Q2 20 | Aug 12, 2026 |
| DYAI | PRESS-RELEASE | bearish | 7/10 | Dyadic International reported Q2 2026 revenue of $961,138, essentially flat year-over-year (-0.6%), and a net loss of $2 | Aug 12, 2026 |
| IPSC | 8-K | neutral | 5/10 | Century Therapeutics reported Q2 2026 financial results, with a net loss of $34.6M vs. $32.5M in Q2 2025, and cash of $1 | Aug 12, 2026 |
| APRE | 8-K | neutral | 5/10 | Aprea Therapeutics reported Q2 2026 financial results with a net loss of $3.6M ($-0.07/share), widening from a $3.2M los | Aug 12, 2026 |
| DYAI | 8-K | bearish | 7/10 | Dyadic International reported Q2 2026 revenue of $961,138, essentially flat year-over-year (-0.6%), and a net loss of $2 | Aug 12, 2026 |
| CTTH | 8-K | bullish | 4/10 | CTT Pharmaceutical Holdings received a continuation-in-part (CIP) patent approval from the USPTO for its micelle deliver | Aug 12, 2026 |
| UNCY | 8-K | mixed | 6/10 | Unicycive Therapeutics reported Q2 2026 results with a net loss of $(1.7) million ($(0.06)/share), significantly narrowe | Aug 12, 2026 |
| ADAG | 6-K | neutral | 5/10 | Adagene reported H1 2026 financial results showing a net loss of $16.4M (vs $13.5M in H1 2025) with $1.6M in licensing r | Aug 12, 2026 |
| LKFT | 6-K | mixed | 6/10 | Lakefront Biotherapeutics reported H1 2026 results showing a net profit of €16.6M vs a €259.1M loss a year ago, driven b | Aug 12, 2026 |
| IPSC | PRESS-RELEASE | bearish | 5/10 | Century Therapeutics reported Q2 2026 EPS of -$0.17, a 55.3% miss vs consensus of -$0.11, with no revenue. The company h | Aug 12, 2026 |
| ALT | PRESS-RELEASE | neutral | 5/10 | Altimmune reported Q2 2026 net loss of $0.12 per share, beating consensus of -$0.13 by 7.7%, but this is a mechanical ar | Aug 12, 2026 |
| ADAG | PRESS-RELEASE | mixed | 6/10 | Adagene reported H1 2026 net loss of $16.4M, wider than $13.5M in H1 2025, with EPS of -$0.23 vs consensus -$0.08 (a 187 | Aug 12, 2026 |
| ABUS | PRESS-RELEASE | bullish | 7/10 | Arbutus Biopharma reported Q2 2026 revenue of $1.0M (down from $10.7M YoY due to the prior year's Qilu partnership reven | Aug 12, 2026 |
| XLO | PRESS-RELEASE | bullish | 7/10 | Xilio Therapeutics reported Q2 2026 collaboration revenue of $18.7M (up 131% YoY) and a net loss of $6.4M (improved from | Aug 12, 2026 |
| ABUS | 8-K | bullish | 7/10 | Arbutus Biopharma reported Q2 2026 results with a net loss of $5.1M ($-0.03 EPS) vs net income of $2.5M ($0.01 EPS) in Q | Aug 12, 2026 |
| MIST | 8-K | bearish | 6/10 | Milestone Pharmaceuticals reported Q2 2026 results with product revenue of $0.6M, up from zero a year ago, but net loss | Aug 12, 2026 |
| XLO | 8-K | bullish | 7/10 | Xilio Therapeutics reported Q2 2026 results with collaboration revenue of $18.7M (up 131% YoY) and a net loss of $6.4M ( | Aug 12, 2026 |
| ALT | 8-K | neutral | 5/10 | Altimmune reported Q2 2026 results with a net loss of $0.12 per share, beating consensus estimates of -$0.13 by 7.7%. Th | Aug 12, 2026 |
| LQDA | PRESS-RELEASE | bearish | 6/10 | Liquidia reported Q2 2026 net product sales of $170.4M (+31% QoQ), net income of $74.7M ($0.74 diluted EPS), and adjuste | Aug 12, 2026 |
| PHVS | PRESS-RELEASE | neutral | 5/10 | Pharvaris reported Q2 2026 results with a loss per share of €0.70, slightly above the consensus EPS estimate of -$0.65 ( | Aug 12, 2026 |
| ANNX | PRESS-RELEASE | bullish | 6/10 | Annexon reported Q2 2026 EPS of -$0.28, slightly wider than the prior year's -$0.34 loss, but the focus is on pipeline c | Aug 12, 2026 |
| STRO | PRESS-RELEASE | mixed | 6/10 | Sutro Biopharma reported Q2 2026 revenue of $9.8M (down 84.6% YoY from $63.7M) and a net loss of $38.5M (-$2.33 EPS), si | Aug 12, 2026 |
| HUMA | PRESS-RELEASE | bullish | 7/10 | Humacyte reported Q2 2026 EPS of -$0.09, beating consensus of -$0.10 by 12.9%, with Symvess product revenue of $0.4M (up | Aug 12, 2026 |
| LXEO | PRESS-RELEASE | neutral | 5/10 | Lexeo Therapeutics reported Q2 2026 net loss of $0.30 per share, in line with the $0.28 consensus estimate. The key cata | Aug 12, 2026 |
| TCRX | PRESS-RELEASE | bearish | 6/10 | TScan Therapeutics reported Q2 2026 EPS of -$0.23, a 15% miss vs consensus of -$0.20, and revenue of $1.1M, sharply down | Aug 12, 2026 |
| ABOS | PRESS-RELEASE | bearish | 5/10 | Acumen Pharmaceuticals reported Q2 2026 EPS of -$0.45 (GAAP), missing the Street consensus of -$0.39, while net loss nar | Aug 12, 2026 |
| TECH | PRESS-RELEASE | neutral | 4/10 | Bio-Techne reported Q4 FY2026 adjusted EPS of $0.52, a 2.1% beat vs $0.52 consensus, on revenue of $321.2M (1% reported | Aug 12, 2026 |
| PLX | 8-K | neutral | 5/10 | Protalix reported Q2 2026 revenue of $19.9M, beating the $12.9M consensus, and EPS of $0.05, beating the $-0.01 consensu | Aug 12, 2026 |
| ANNX | 8-K | bullish | 6/10 | Annexon reported Q2 2026 results with a net loss of $0.28/share, slightly wider than the prior year's $0.34/share loss, | Aug 12, 2026 |